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David I. Marks,1 Karen Ballen,2 Brent R Logan,3 Zhiwei Wang,3 Kathleen A. Sobocinski,3
Andrea Bacigalupo,4 Linda J. Burns,5 Vikas Gupta,6 Vincent Ho,7 Philip L. McCarthy,8
Olle Ringden,9 Harry C. Schouten,10 Matthew Seftel,11 J. Douglas Rizzo3Using the Center for Internaitonal Blood andMarrow Transplant Research (CIBMTR) data, we compared the
transplant outcomes of patients with chronic myelogenous leukemia (CML) who were nonsmokers (NS) and
past or current smokers (PCS). There were 2193 NS and 625 PCS who received matched sibling and unre-
lated donor allografts for CML in first chronic phase. We looked for dose effects and identified low and high
dose smoking groups (.10 pack years, .1 pack per day). Outcomes were adjusted for known prognostic
variables including the European Group for Blood and Marrow Transplant (EBMT) risk score. In multivariate
analyses of sibling allograft recipients, relapse risk (RR) was higher (RR5 1.67, P5.003) in smokers than NS,
but the dose effects were not consistent. High-dose smokers experienced a 50% treatment-related mortality
(TRM) versus 28% in the NS group at 5 years on univariate analysis, and the RR was 1.57 (P5.005) on mul-
tivariate analysis. Overall survival (OS) at 5 years was 68% in NS versus 62% in the low-dose smoking group
versus 50% in the high-dose smoking group (P\.001). Smoking did not significantly affect outcomes in un-
related donor recipients, but numbers were smaller. High-dose smoking is associated with a reduction in OS
in patients having sibling allografts for CML. A prospective study with detailed demographic, pulmonary func-
tion, and quality-of-life data would improve our understanding of this issue.
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Allogeneic stem cell transplantation is widely used
to cure patients with leukemia and other hematologic
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6/j.bbmt.2009.06.005transplant outcome of patients with chronic myeloge-
nous leukemia (CML). These include patient age [1]
(Center for International Blood and Marrow Trans-
plant Research [CIBMTR], unpublished data), perfor-
mance status at transplant [2], and body mass index [1].
Pretransplant pulmonary function may also affect
overall transplant outcome and posttransplant respira-
tory complications [3,4]. One of the major causes of
pretransplant respiratory abnormalities is cigarette
smoking. Depending on the population studied, be-
tween 20% and 50% of adult allogeneic transplant
candidates have a current smoking history, and many
additional patients have a past smoking history. Smok-
ing, as well as affecting pulmonary function, can influ-
ence the risk of coronary artery disease [5], and is an
important cause of lung cancer (which may be in-
creased after allogeneic transplantation) [6]. Smokers
are known to have different demographics than non-
smokers (NS). They are more likely to be male, of
a lower socioeconomic status [7,8], and have a higher
alcohol intake [9]. In studies of the effect of smoking
on health outcomes, it is possible that these associa-
tions of smoking may affect the outcomes.
No large-scale studies address the effect of smok-
ing on transplant outcome. The CIBMTR database,1277
1278 Biol Blood Marrow Transplant 15:1277-1287, 2009D. I. Marks et al.which includes data on smoking history, is ideal for
this purpose. We hypothesized that a smoking history
would significantly reduce the chance of a successful
transplant outcome by increasing treatment-related
mortality (TRM), primarily through pulmonary com-
plications, including infection. Relapse incidence was
also studied because physicians may have altered con-
ditioning in patients who smoke. Smoking may affect
the incidence of secondary malignancies, but this study
was not designed to address this issue.
We elected to study patients with CML in first
chronic phase (CP1), because we hypothesized that
examining the effect of smoking in a chemotherapy
naı¨ve population would ‘‘isolate’’ the effect of smoking.
Smoking might make pulmonary complications more
likely after pretransplant chemotherapy, but we wished
to study the effect of smoking on transplant alone.
This focus on CML also eliminated a potential source
of patient heterogeneity, and the prognostic factors
affecting the transplant outcome of CML patients
are well described [10]. We analyzed sibling and unre-
lated donor transplants separately, as the latter has a
greater TRM and may have received higher doses of
total body irradiation (TBI).
There are numerous practical implications of
performing this study. Transplant teams will be able
to inform better patients who smoke about the chances
of a successful outcome.The studymay generate infor-
mation that enables transplanters to modify condition-
ing regimens to increase the chance of a successful
outcome. Finally, when the causes of treatment failure
are determined, transplanters may be able to direct
their supportive care efforts to preventing specific
problems.PATIENT SELECTION AND INCLUSION
CRITERIA
Patient data for this study were obtained from the
CIBMTR. More than 500 participating centers regis-
ter consecutive allogeneic transplants to CIBMTR.
Detailed demographic and clinical data are collected
on a sample of registered patients. Compliance is mon-
itored by on-site audits. Computerized error checks,
physician reviews of submitted data, and on-site audits
of centers ensure the quality of data.
This study included all patients between 1990 and
2004, aged 18 years and above, who received HLA-
identical sibling or matched unrelated donor (MUD)
allogeneic transplants for CML in CP1 for whom
a smoking history was known. Patients received busul-
phan (Bu) and cyclophosphamide (Cy) or TBI and Cy
for conditioning. Graft type was restricted to bone
marrow (BM) or peripheral blood (PB). Graft-versus-
host disease (GVHD) prophylaxis was restricted to cy-
closporine (CsA) andmethotrexate (MTX), tacrolimusand MTX, T cell depletion, or CsA and other immu-
nosuppressive agents. Patients who received low-
dose oral Bu prior to transplant were excluded.
The number of patients with CML in CP1 aged
.18 years who had allografts reported to the
CIBMTR between 1990 and 2004 was 5461. A total
of 5022 patients received a sibling or MUD allograft
of BM or PB. We only included the 4409 receiving
Cy/TBI or Bu/Cy conditioning and excluded the pa-
tients who had received prior low-dose Bu, leaving
3880 patients. We confined our study to 3793 patients
with specific types of GVHD prophylaxis (defined
before). Finally, we had quantitative smoking informa-
tion for 2818 of these patients.Smoking Data
Patients were categorized as NS or past or current
smokers (PCS) based on self-reported responses
extracted from medical notes by data managers com-
pleting the CIBMTR forms. The questions, which
asked about smoking history, varied slightly in 1989,
1995, and 2002. However, all questionnaire versions
enquired about duration and number of cigarettes per
day. The quantitative data regarded number of years
smoked and amount per day (\1 pack, 1 pack and .1
pack) enabling us to compare the major outcomes in
these groups and look for a dose effect. In this study
PCS are termed ‘‘smokers.’’ We divided smokers into
2 ‘‘doses’’: high-dose smokers had accumulated .10
pack years and smoked .1 pack per day, and low-
dose smokers had #10 pack years or #1 pack per day.Statistical Methods
Patient-, disease-, and treatment-related variables
for patients in the 3 smoking groups were compared
using chi-square test for categoric variables and the
Kruskal-Wallis test for continuous variables. P-values
for pair-wise comparison were adjusted using Bonfer-
roni correction.
The primary endpoints were relapse, TRM, dis-
ease-free survival (DFS), and overall survival (OS).
The event relapse was defined as occurrence of CML
(clinical and/or cytogenetic) posttransplant. TRM
was defined as death within 28 days posttransplant or
death without CML relapse. Smoking may affect the
incidence of fungal infection, but because our data
does not allow us to verify this diagnosis, this was
not an endpoint of the study.
Probabilities of TRM and relapse were calculated
using the cumulative incidence function method [11].
Treatment-related death and relapse were the compet-
ing events. Data on patients without either competing
event were censored at last follow-up. For analyses of
survival, death from any cause was considered an event
and surviving patients were censored at last follow-up.
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event.
All P values were 2 sided, and a value of\.05 was
considered statistically significant.
Cox proportional hazards models were used to
adjust for patient-related, disease-related, and treat-
ment-related covariates. A main effect term for
smoking was forced into the model. The remaining
covariates were included using a stepwise forward
selection technique with a value of P # .05 as the cri-
terion for inclusion in the final models. Other variables
considered in the models include: recipient age, sex,
region of transplant center, performance score, white
blood cells (WBC) at diagnosis, body mass index prior
to transplant, spleen size at diagnosis, pretransplant
use of hydroxyurea, interferon, or gleevec, interval
from diagnosis to transplant, year of transplant, HLA
matching, conditioning regimen, use of antithymocyte
globulin (ATG) or alemtuzamab antibody therapy
prior to transplant, use of lung shielding in radiation
therapy, GVHD prophylaxis, donor age, donor-recip-
ient sex match, source of graft, European Group for
Blood andMarrow Transplant (EBMT) risk score, cy-
tomegalovirus (CMV) status, and coexisting disease.
The EBMT risk score is a scoring system designed
by the European Group for Blood andMarrow Trans-
plantation to predict the survival after allogeneic trans-
plant for CML patient [10]. Higher score indicates
a lower probability of survival. The CIBMTR does
not collect sufficient data to calculate a Sokol score.
Pulmonary function test data is not routinely collected
by CIBMTR.
The proportional hazards assumption for each
variable was examined using time-varying covariate
and graphical approaches. Stratified proportional
hazards models were used when variables with non-
proportional hazards were identified. No significant
interactions between smoking and other explanatory
variables were found. There were no statistically sig-
nificant center effects. In addition to the comparison
of NS with PCS, we also considered models with sub-
groups of PCS based on years smoked and average
packs per day. The cut point for years smoked (#10
years versus .10 years) was selected based on plots
of the Martingale residuals. Because age is related to
duration of smoking, we tested for confounding by an-
alyzing the subgroup of patients 30 years of age and
older to determine consistency of effect relative to
the group of all patients. Analyses were performed
with the use of SAS software, version 9.1 (SAS Insti-
tute, Cary, NC).
Because data regarding smoking exposure was lim-
ited, we considered 5 models in looking for an effect of
smoking. First, we simply compared PCS andNS. Sec-
ond, PCS were divided according to duration of smok-
ing (#10 years and .10 years). Third, the average
number of packs per day was divided into\1 pack, 1pack, .1 pack. Fourth, we compared smokers with
.10 pack years and#10 pack years. In the fifth model,
we combined models 2, 3, and 4 and compared low-
and high-dose smokers as stated above. This results
and discussion will be focused on the fifth model.RESULTS
Patient Characteristics in Sibling Allograft
Recipients
Table 1 shows the characteristics of patients .18
years with CML who had sibling donor transplants,
and compares NSs and those who are low- or high-
dose smokers. Table 2 shows similar data for recipients
of unrelated donor transplants. We divided smokers
into 2 ‘‘doses.’’ In the sibling allograft recipients,
high-dose smokers (n5 94) had accumulated .10
pack years and smoked .1 pack per day, and low-
dose smokers (n5 370) had #10 pack years or #1
pack per day. Overall, the median number of years of
smoking was 15 years, and 22% smoked .1 pack per
day.
Overall, in the sibling allograft group, high-dose
smokers compared to NS were slightly older, more
were male (72% versus 54%), had a lower diagnostic
white cell count (WCC), slightly more were female-
to-male transplants (27% versus 22%) and had a higher
EBMTrisk score (83%versus 66%were 2-4,P\.001).
Fewer high-dose smokers had no coexisting medical
diseases (52% versus 78%, P\ .001).
There was no evidence that the transplants were
performed differently in smokers; cytotoxic drug doses
were similar in the 2 groups as was the dose of TBI, and
there was no difference in lung shielding.
Major Outcomes on Univariate Analysis
In the matched sibling donor group, survival at
5 years was significantly lower in the high-dose smoker
group (50%) compared to theNS and low-dose smoker
groups (68% and 62%, respectively) (Table 3 and Fig-
ure 1).DFSwas 20% lower in the high-dose group than
the BS group (44% versus 64%, P\ .001). TRM at 5
years was similar in the nonsmoker and low-dose
smoker groups (28% versus 32%), but considerably
higher in the high-dose smoker group (50%, P \
.001). The absolute 5-year incidence of relapse is sim-
ilar in the NS and low- and high-dose smoker groups
(8% versus 10% vesus 6%, respectively). There are
no differences in the incidence of bronchopneumonia,
interstitial pneumonitis (IP), and broncholitis obliter-
ans among the 3 groups (Table 3). There were no sig-
nificant interactions between smoking and
conditioning regimen (P5 .309 for TRM) or between
smoking and GVHD prophylaxis (P5 .310 for TRM).
Although TRM was higher and DFS and OS were
lower in the high-dose recipients of unrelated donor
Table 1. Characteristics of Patients$18 Years Receiving HLA-Identical Sibling Donor Rransplants for CML in First Chronic Phase,
Reported to the CIBMTR, 1990-2004
Smokers
Nonsmokers Low Dose* High Dose*
Variables N N (%) N N (%) N N (%)
Number of patients 1649 370 94
Age at transplant, years, median (range) 1649 37 (18-61) 370 38 (18-66) 94 45 (22-58)
Age at transplant, years 1649 370 94
18-29 419 (25) 67 (18) 6 (6)
30-39 580 (35) 134 (36) 22 (23)
40-49 466 (28) 115 (31) 48 (51)
$ 50 184 (11) 54 (15) 18 (19)
Male 1649 888 (54) 370 262 (71) 94 68 (72)
Region 1648 370 94
United States 499 (30) 126 (34) 53 (56)
Canada 60 (4) 14 (4) 8 (9)
Europe 594 (36) 141 (38) 20 (21)
Asia 143 (9) 20 (5) 4 (4)
Australia/New Zealand 88 (5) 13 (4) 3 (3)
Mideast/Africa 139 (8) 12 (3) 3 (3)
Central/South America 125 (8) 44 (12) 3 (3)
Karnofsky score (< 90%) 1637 171 (10) 366 42 (11) 92 15 (16)
Number of packs per day 370 94
# 1 – 363 (98) –
> 1 – 7 (2) 94 (100)
Number of years smoked, median (range) – 370 12 (1-43) 94 20 (5-44)
Smoking pack-year,median (range) – 370 10 (<1-43) 94 34 (12-140)
Smoking pack-year, 370 94
# 10 pack-year – 222 (60) –
> 10 pack-year – 148 (40) 94 (100)
Body mass index, kg/m2 1635 369 94
# 22 380 (23) 69 (19) 19 (20)
22-30 1012 (62) 238 (64) 59 (63)
> 30 243 (15) 62 (17) 16 (17)
White cell count at diagnosis, 109/L,
median (range)
1529 145 (1-800) 347 114 (7-650) 89 96 (4-387)
White cell count at diagnosis, 109/L 1529 347 89
< 50 282 (18) 91 (26) 26 (29)
50-100 290 (19) 68 (20) 24 (27)
> 100 957 (63) 188 (54) 39 (44)
Spleen size at diagnosis 1477 342 81
Normal 467 (32) 127 (37) 31 (38)
Enlarged 1010 (68) 215 (63) 50 (62)
Coexisting diseases 1646 369 94
Cardiac and pulmonary 9 (1) 2 (1) 4 (4)
Cardiac 107 (7) 32 (9) 14 (15)
Pulmonary 28 (2) 12 (3) 7 (7)
Other 214 (13) 60 (16) 20 (21)
None 1288 (78) 263 (71) 49 (52)
Pretransplant therapy for CML
Hydroxyurea 1634 1510 (92) 368 333 (90) 94 78 (83)
Interferon 1205 578 (48) 269 127 (47) 75 33 (44)
Imatinib 1648 50 (3) 370 9 (2) 94 4 (4)
Time from diagnosis to transplant, months,
median (range)
1649 8 (<1-127) 370 9 (1-72) 94 7 (2-99)
Time from diagnosis to transplant, months 1649 370 94
< 6 522 (32) 108 (29) 38 (40)
6-11 591 (36) 138 (37) 31 (33)
12-23 380 (23) 90 (24) 18 (19)
$ 24 156 (9) 34 (9) 7 (7)
EBMT risk score 1647 370 94
0-1 572 (35) 92 (25) 16 (17)
2 717 (44) 171 (46) 48 (51)
3 322 (20) 91 (25) 26 (28)
4 36 (2) 16 (4) 4 (4)
Year of transplant 1649 370 94
1990-1994 746 (45) 155 (42) 44 (47)
1995-1999 655 (40) 173 (47) 44 (47)
2000-2004 248 (15) 42 (11) 6 (6)
Conditioning regimen 1649 370 94
(Continued )
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Table 1. (Continued )
Smokers
Nonsmokers Low Dose* High Dose*
Variables N N (%) N N (%) N N (%)
TBI/Cy ± other 591 (36) 124 (34) 36 (38)
Bu/Cy ± other (no TBI) 1058 (64) 246 (66) 58 (62)
Dose of Cy,† mg/kg 1432 320 76
120 1267 (88) 279 (87) 65 (86)
200 165 (12) 41 (13) 11 (14)
Dose of Bu, mg/kg 1627 366 93
No Bu 591 (36) 124 (34) 36 (39)
< 12 59 (4) 6 (2) 5 (5)
12-16 304 (19) 72 (20) 23 (25)
16-17 613 (38) 157 (43) 25 (27)
$ 17 60 (4) 7 (2) 4 (4)
Dose of TBI, cGy 1603 352 86
Non-TBI 1058 (66) 246 (70) 58 (67)
< 1300 421 (26) 79 (22) 18 (21)
$ 1300 124 (8) 27 (8) 10 (12)
GVHD prophylaxis 1649 370 94
T depl ± other 102 (6) 25 (7) 9 (10)
FK506 ± other 58 (4) 10 (3) 4 (4)
MTX + CsA ± other 1324 (80) 293 (79) 66 (70)
CsA ± other (no MTX) 165 (10) 42 (11) 15 (16)
Donor age 1580 352 88
# 29 460 (29) 73 (21) 8 (9)
30-39 534 (34) 123 (35) 25 (28)
40-49 405 (26) 98 (28) 40 (45)
$ 50 181 (11) 58 (16) 15 (17)
Sex match 1647 370 94
Male into male 523 (32) 141 (38) 43 (46)
Male into female 405 (25) 55 (15) 16 (17)
Female into male 365 (22) 121 (33) 25 (27)
Female into female 354 (21) 53 (14) 10 (11)
Donor-recipient CMV status 1555 350 91
2 / 2 391 (25) 89 (25) 24 (26)
2 /+ 200 (13) 45 (13) 14 (15)
+/ 2 183 (12) 40 (11) 10 (11)
+/+ 781 (50) 176 (50) 43 (47)
Graft type 1649 370 94
BM 1331 (81) 301 (81) 78 (83)
PB ± BM 318 (19) 69 (19) 16 (17)
Use of ATG or Campath 1627 15 (1) 365 3 (1) 94 4 (4)
Lung shielding in radiation therapy 1587 262 (17) 360 50 (14) 92 11 (12)
Follow-up of surviving patients, month 1649 91 (2-209) 370 98 (1-199) 94 115 (19-193)
CML indicates chronic myelogenous leukemia; TBI, total body irradiation; Cy, cyclophosphamide; Bu, busulfan; GVHD, graft-versus-host disease; MTX,
methotrexate; CsA, cyclosporine; BM, bone marrow; PB, peripheral blood; CIBMTR, Center for International Blood and Marrow Transplant Research;
ATG, antithymocyte globulin; EBMT, European Group for Blood and Marrow Transplant.
Duration of follow-up:
Nonsmoker: $1 year5 73%; $3 year5 61%;$ 5 year5 50%.
Low-dose smoker: $ 1 year5 69%; $3 year5 59%;$ 5 year5 49%.
High-dose smoker: $ 1 year5 70%; $3 year5 46%;$ 5 year5 45%.
*Low-dose smokers5 smoking#10 pack-years or >10 pack-years with# 1 pack/day; high-dose smokers5 smoking >10 pack-years with >1 pack/day.
†Cy dose range 100-150 mg/kg classified as 120 mg/kg; Cy dose $150 mg/kg classified as 200 mg/kg.
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respectively); this may relate to there being only 30
such patients.
Multivariate Analysis of Major Outcomes in
Sibling Allograft Group
Relapse
PCS overall had a higher relative risk (RR) of re-
lapse (RR5 1.67, P5 .003). There was some evidenceof a dose effect, although this was not consistent. More
than 10 years smoking duration was associated with
a higher RR of relapse; however, a higher number of
packs smoked per day (data not shown) or high-dose
smoking overall were not associated with a higher
chance of relapse. There was no difference in the
incidence of acute GVHD (aGVHD) and chronic
GVHD (cGHVD) in PCS and NCS (58% versus
57% and 51% versus 50%, respectively, P5 .60 and
.46. respectively).
Table 2. Characteristics of Patients $18 Years Receiving Matched Unrelated Donor Transplants for CML in First Chronic Phase,
Reported to the CIBMTR, 1990-2004
Smokers
Nonsmokers L.ow Dose* High Dose*
Variables N N (%) N N (%) N N (%)
Number of patients 544 131 30
Age at transplant, years, median (range) 544 34 (18-61) 131 37 (19-58) 30 43 (19-53)
Age at transplant, years 544 131 30
18-29 165 (30) 30 (23) 2 (7)
30-39 214 (39) 46 (35) 8 (27)
40-49 145 (27) 45 (34) 15 (50)
$ 50 20 (4) 10 (8) 5 (17)
Male 544 317 (58) 131 89 (68) 30 24 (80)
Region 544 131 30
United States 173 (32) 52 (40) 19 (63)
Canada 31 (6) 8 (6) 2 (7)
Europe 245 (45) 56 (43) 7 (23)
Asia 54 (10) 13 (10) 1 (3)
Australia/New Zealand 20 (4) 1 (1) 0 (0)
Mideast/Africa 8 (1) 0 (0) 0 (0)
Central/South America 13 (2) 1 (1) 1 (3)
Karnofsky score (<90%) 535 49 (9) 131 11 (8) 30 5 (17)
Number of packs per day 131 30
# 1 – 131 (100) –
> 1 – – 30 (100)
Number of years smoked, median (range) – 131 15 (2-35) 30 20 (6-35)
Smoking pack-year, median (range) – 131 10 (1-35) 30 35 (12-93)
Smoking pack-year 131 30
# 10 pack-year – 66 (50) –
> 10 pack-year – 65 (50) 30 (100)
Body mass index, kg/m2 535 126 30
# 22 116 (22) 31 (25) 5 (17)
22-30 338 (63) 73 (58) 17 (57)
> 30 81 (15) 22 (17) 8 (27)
White cell count at diagnosis, 109/L,
median (range)
487 150 (4-790) 115 126 (1-779) 30 116 (19-334)
White cell count at diagnosis, 109/L 487 115 30
< 50 84 (17) 34 (30) 6 (20)
50-100 83 (17) 17 (15) 7 (23)
> 100 320 (66) 64 (56) 17 (57)
Spleen size at diagnosis 452 108 26
Normal 147 (33) 53 (49) 9 (35)
Enlarged 305 (67) 55 (51) 17 (65)
Coexisting diseases 543 131 30
Cardiac and Pulmonary 3 (1) 0 (0) 0 (0)
Cardiac 26 (5) 8 (6) 5 (17)
Pulmonary 9 (2) 3 (2) 3 (10)
Other 78 (14) 18 (14) 5 (17)
None 427 (79) 102 (78) 17 (57)
Pretransplant therapy for CML
Hydroxyurea 538 507 (94) 130 114 (88) 30 24 (80)
Interferon 479 308 (64) 118 86 (73) 25 17 (68)
Imatinib 543 48 (9) 131 5 (4) 30 0 (0)
Time from diagnosis to transplant, months,
median (range)
544 15 (1-111) 131 16 (3-95) 30 17 (6-39)
Time from diagnosis to transplant, months 544 131 30
< 6 50 (9) 6 (5) 0 (0)
6-11 145 (27) 38 (29) 11 (37)
12-23 180 (33) 54 (41) 14 (47)
$ 24 169 (31) 33 (25) 5 (17)
EBMT risk score 526 122 28
0-1 10 (2) 0 (0) 1 (4)
2 130 (25) 21 (17) 0 (0)
3 226 (43) 52 (43) 12 (43)
4 144 (27) 42 (34) 12 (43)
5 16 (3) 7 (6) 3 (11)
Year of transplant 544 131 30
1990-1994 192 (35) 59 (45) 17 (57)
1995-1999 228 (42) 57 (44) 13 (43)
2000-2004 124 (23) 15 (11) 0 (0)
(Continued )
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Table 2. (Continued )
Smokers
Nonsmokers L.ow Dose* High Dose*
Variables N N (%) N N (%) N N (%)
Conditioning regimen 544 131 30
TBI/Cy ± other 409 (75) 100 (76) 26 (87)
Bu/Cy ± other (no TBI) 135 (25) 31 (24) 4 (13)
Degree of matching 538 130 29
Well Matched 68 (13) 19 (15) 5 (17)
Partially matched 162 (30) 40 (31) 13 (45)
Mismatched 211 (39) 57 (44) 9 (31)
Unknown 97 (18) 14 (11) 2 (7)
Dose of Cy,† mg/kg 466 107 23
120 415 (89) 93 (87) 21 (91)
200 51 (11) 14 (13) 2 (9)
Dose of Bu, mg/kg 542 129 30
No Bu 409 (75) 100 (78) 26 (87)
< 12 13 (2) 0 (0) 0 (0)
12-16 28 (5) 6 (5) 0 (0)
16-17 85 (16) 21 (16) 3 (10)
$ 17 7 (1) 2 (2) 1 (3)
Dose of TBI, cGy 523 124 29
Non-TBI 135 (26) 31 (25) 4 (14)
< 1300 251 (48) 65 (52) 13 (45)
$ 1300 137 (26) 28 (23) 12 (41)
GVHD prophylaxis 544 131 30
T depl ± other 117 (22) 29 (22) 7 (23)
FK506 ± other 67 (12) 10 (8) 3 (10)
MTX +CsA ± other 344 (63) 87 (66) 19 (63)
CsA ± other (no MTX) 16 (3) 5 (4) 1 (3)
Donor age 465 105 24
# 29 132 (28) 20 (19) 6 (25)
30-39 180 (39) 54 (51) 10 (42)
40-49 134 (29) 26 (25) 5 (21)
$ 50 19 (4) 5 (5) 3 (13)
Gender match 532 124 28
Male into male 213 (40) 57 (46) 12 (43)
Male into female 122 (23) 30 (24) 3 (11)
Female into male 97 (18) 26 (21) 10 (36)
Female into female 100 (19) 11 (9) 3 (11)
Donor-recipient CMV status 513 121 26
2 /2 183 (36) 39 (32) 9 (35)
2 /+ 116 (23) 40 (33) 4 (15)
+/2 81 (16) 11 (9) 4 (15)
+/+ 133 (26) 31 (26) 9 (35)
Graft type 544 131 30
BM 505 (93) 127 (97) 29 (97)
PB ± BM 39 (7) 4 (3) 1 (3)
Use of ATG or Campath 505 172 (34) 121 33 (27) 28 8 (29)
Lung shielding in radiation therapy 505 170 (34) 119 43 (36) 29 13 (45)
Follow-up of surviving patients, months 544 79 (4-194) 131 90 (4-195) 30 109 (13-157)
CML indicates chronic myelogenous leukemia; TBI, total body irradiation; Cy, cyclophosphamide; Bu, busulfan; GVHD, graft-versus-host disease; MTX,
methotrexate; CsA, cyclosporine; BM, bone marrow; PB, peripheral blood; CIBMTR, Center for International Blood and Marrow Transplant Research;
ATG, antithymocyte globulin; EBMT, European Group for Blood and Marrow Transplant; CMV, cytomegalovirus.
Duration of follow-up:
Nonsmoker: $1 year5 55%; $3 year5 43%;$ 5 year5 31%.
Low-dose smoker: $1 year5 53%; $3 year5 41%;$ 5 year5 33%.
High-dose smoker: $1 year5 54%; $3 year5 34%;$ 5 year5 27%.
*Low-dose smokers5 smoking#10 pack-years or >10 pack-years with#1 pack/day; high-dose smokers5 smoking >10 pack-years with >1 pack/day.
†Cy dose range 100-150 mg/kg classified as 120 mg/kg, Cy dose $150 mg/kg classified as 200 mg/kg.
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A multivariate analysis comparing TRM in sibling
allograft recipients is shown in Table 4. The relative risk
of TRM is not different between NS and PCS overall.
However, high-dose smoking was strongly associated
with a higher TRM (RR5 1.57, P5 .005).The effect of smoking on risk of TRM is signifi-
cantly increased among 28-day survivors (RR5 1.65,
P5 .002), and, importantly, remains elevated for
100-day survivors (RR5 1.81, P5 .002) and 1-year
survivors (RR5 3.29, P\ .001), suggesting a consis-
tent effect over time.
Table 3. Univariate Outcome of Patients$18 Year Receiving Allogeneic Transplants for CML in First Chronic Phase, Reported to
the CIBMTR, 1990-2004
HLA-Matched Siblings Donor Unrelated Donor
Smoker Group*
Outcomes N
Never
(95% CI) N
Low Dose
(95% CI) N
High Dose
(95% CI) P-Value N
Never
(95% CI) N
Low Dose
(95% CI) N
High Dose
(95% CI) P-Value
Relapse 1565 347 88 514 119 30 .837
100 days 1 (0-1) 1 (0-3) 0 .013 1 (0-2) 1 (0-3) 0
1 year 3 (2-4) 6 (4-9) 3 (1-8) 3 (2-5) 3 (1-8) 0
3 years 6 (5-8) 9 (6-12) 3 (1-8) 6 (4-8) 5 (2-10) 0
5 years 8 (7-9) 10 (7-14) 6 (2-12) 7 (5-9) 5 (2-10) 0†
TRM 1565 347 88 <.001 514 119 30 .200
100 days 12 (10-13) 11 (8-15) 17 (10-26) 23 (19-26) 19 (13-27) 33 (18-51)
1 year 22 (20-25) 24 (20-29) 28 (20-38) 41 (37-46) 42 (33-51) 57 (39-74)
3 years 27 (24-29) 29 (24-34) 41 (31-52) 46 (42-51) 48 (39-57) 64 (46-80)
5 years 28 (25-30) 32 (27-37) 50 (40-61) 49 (44-53) 50 (41-59) 68 (50-83)
DFS 1565 347 88 <.001 514 119 30 .293
100 days 88 (86-89) 87 (83-90) 83 (74-90) 76 (72-80) 80 (72-86) 67 (49-82)
1 year 75 (73-77) 70 (65-75) 68 (58-77) 56 (51-60) 54 (45-63) 43 (26-61)
3 years 67 (65-69) 63 (57-68) 55 (45-66) 48 (43-52) 47 (37-56) 36 (20-54)
5 years 64 (62-67) 58 (52-63) 44 (33-54) 44 (40-49) 44 (35-54) 32 (17-50)
Bronchopneumonia 1575 363 88 .602 512 129 30 .963
100 days 10 (8-11) 12 (9-16) 11 (6-19) 16 (13-19) 15 (9-21) 10 (2-23)
1 year 18 (16-20) 17 (14-21) 19 (11-28) 25 (21-29) 26 (18-34) 23 (10-40)
3 years 23 (21-25) 23 (19-28) 26 (17-36) 30 (26-35) 29 (21-37) 31 (16-48)
5 years 25 (22-27) 26 (21-31) 26 (17-36) 30 (26-35) 31 (23-40) 31 (16-48)
IPN 1634 359 94 .018 534 129 29 .671
100 days 6 (5-7) 8 (5-11) 14 (8-22) 13 (10-16) 12 (7-19) 14 (4-28)
1 year 11 (10-13) 12 (9-15) 21 (13-30) 20 (16-23) 17 (11-25) 21 (8-37)
3 years 12 (11-14) 14 (10-18) 21 (13-30) 21 (17-24) 18 (12-26) 25 (11-42)
5 years 13 (11-15) 15 (11-19) 21 (13-30) 21 (18-25) 18 (12-26) 25 (11-42)
BO 1320 298 78 .731 444 104 25 .473
100 days 0 (0-1) 0 1 (0-5) 0 (0-1) 0 (0-100) 0 (0-100)
1 year 2 (1-3) 3 (1-5) 3 (0-7) 3 (2-5) 2 (0-6) 0 (0-100)
3 years 4 (3-5) 4 (2-7) 4 (1-10) 5 (3-7) 2 (0-6) 8 (0-27)
5 years 4 (3-6) 5 (2-8) 6 (2-13) 5 (3-8) 2 (0-6) 8 (0-27)
Overall survival 1649 370 88 <.001 512 119 30 .278
100 days 88 (86-89) 88 (84-91) 83 (74-90) 76 (72-79) 80 (71-86) 67 (49-82)
1 year 76 (74-78) 73 (69-78) 72 (62-80) 56 (52-60) 56 (47-65) 43 (26-61)
3 years 70 (68-73) 66 (62-71) 59 (48-69) 50 (46-54) 48 (39-57) 36 (20-54)
5 years 68 (66-70) 62 (57-67) 50 (40-61) 46 (41-50) 46 (37-55) 32 (17-50)
TRM indicates treatment-related mortality; DFS, disease-free survival; IPN, interstitial pneumonitis; BO, broncholitis obliterans; CI, confidence interval.
Note: Comparing nonsmoker and low-dose smoker versus high-dose smoker in the unrelated donor group:
Relapse: P-value5 .685.
TRM: P-value5 .074.
Overall survival: P-value5 .115.
*Low-dose smokers5 smoking#10 pack-years or >10 pack-years with# 1 pack/day; high-dose smokers5 smoking >10 pack-years with >1 pack/day.
†No relapses were reported for the high-dose smokers in the unrelated donor group, although small sample size and high TRM are important consid-
erations. Confidence intervals are not relevant.
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DFS was shorter in PCS (RR5 1.22, P5 .019).
There were clear dose effects. High-dose smokers
had a significantly shorter DFS (RR5 1.52,
P5 .005, Table 4).
However, OS was only affected by high-dose
smoking (RR5 1.44, P5 .015), and this was con-
firmed by dose effects (Table 4). The distribution of
causes of death, as reported by the hematopoietic cell
transplant (HCT) centers, was similar for the related
and unrelated transplant recipients (Tables 5 and 6).
We further analyzed outcomes in the group of
patients with a Karnofsky score \90 at transplant
and found no differences between PCS and NS (data
not shown).MUD transplant recipients
The clinical characteristics of MUD recipients
are shown in Table 2 and univariate analysis of out-
comes in Table 3. For these analyses we compared
NS and low-dose smokers (combined) with high-
dose smokers. TRM was lower in BS and low-dose
smokers compared to high-dose smokers (49% versus
68%), but this was not significant (P5 .074). Survival
at 5 years in the high-dose group was 32% compared
to 46% in the NS and low-dose smoker groups
(P5 .115). In the multivariate analyses, we compared
NS with PCS (Table 4). There were no differences
in the major outcomes (relapse, TRM, DFS, or OS)
between the 2 groups. Dose effects were also tested
and no significant differences were found.
Figure 1. Probability of OS of patients$18 years receiving HLA-iden-
tical siblings allogeneic transplants for CML in first chronic phase,
reported to the CIBMTR, 1990-2004.
Table 4. Multivariate Analysis Comparing Outcomes among
Patients$18 Years Old Receiving Transplants for CML in First
Chronic Phase, Reported to the CIBMTR, 1990-2004
Variables N Relative Risk (95% CI) P-Value
HLA-identical sibling donor
Relapse*
Nonsmoker 1563 1.00 .008
Past/current smoker†
Low dose 347 1.75 (1.23-2.49) .002
High dose 88 1.02 (0.44-2.36) .960
Treatment-related mortality‡
Nonsmoker 1563 1.00 .008
Past/current smoker
Low dose 347 0.95 (0.77-1.88) .657
High dose 88 1.57 (1.14-2.14) .005
Disease-free survival§
Nonsmoker 1563 1.00 .012
Past/current smoker
Low dose 347 1.14 (0.95-1.37) .162
High dose 88 1.52 (1.14-2.04) .005
Overall survival¶
Nonsmoker 1563 1.00 .049
Past/current smoker
Low dose 370 1.01 (0.84-1.22) .910
High dose 94 1.44 (1.07-1.93) .015
Unrelated donor transplants
Relapset
Nonsmoker 514 1.00
Past/current smoker 149 0.67 (0.28-1.56) .351
Treatment-related mortality**
Nonsmoker 514 1.00
Past/current smoker 149 1.02 (0.79-1.33) .861
Disease-free survival††
Nonsmoker 514 1.00
Past/current smoker 149 0.97 (0.76-1.25) .834
Overall survival‡‡
Nonsmoker 544 1.00
Past/current smoker 161 0.96 (0.75-1.21) .708
CI indicates confidence interval; CML, chronic myelogenous leukemia;
GVHD, graft-versus-host disease; CIBMTR, Center for Internatioinal
Blood and Marrow Transplant Research; WBC, white blood cells.
*Relapse model adjusted for recipient age, gender, region, spleen size at
diagonosis, and GVHD prophylaxis.
†Low-dose smokers5 smoking#10 pack-years or >10 pack-years with
# 1 pack/day; high-dose smokers5 smoking >10 pack-years with >1
pack/day.
‡TRM model adjusted for recipient age, sex, region, karnofsky score,
GVHD prophylaxis, WBC count, EBMT risk score, and graft sources.
Stratified on conditioning regimen/dose group.
§DFS model adjusted for recipient age, sex, region, karnofsky score,
GVHD prophylaxis, and time from diagnosis to transplant. Stratified
on conditioning regimen/dose group.
¶Overall survival model adjusted for recipient age, sex, region, Karnof-
sky score, GVHD prophylaxis, EBMTrisk score, and graft sources. Strat-
ified on conditioning regimen/dose group.
tRelapse model adjusted for recipient age, sex, and region.
**TRM model adjusted for recipient age, sex, region, recipient CMV,
GVHD prophylaxis, and EBMTrisk score.
††DFS adjusted for recipient age, sex, region, recipient CMV, GVHD
prophylaxis, and EBMTrisk score.
‡‡Overall survival model adjusted for recipient age, sex, region,
recipient CMV, year of transplant, GVHD prophylaxis, and EBMT risk
score.
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Smoking has profound effects on health, causing
higher rates of malignancy, cardiac, and pulmonary
disease [12]. Nonetheless, a significant percentage of
transplant candidates will be PCS and physicians take
smoking history as part of the pretransplant evalua-
tion. Some regard smokers as inferior transplant candi-
dates, and in borderline cases it may be a factor in the
decision to proceed to transplant.
The major findings of this study are that in sibling
allograft recipients high-dose smoking (.10 pack years
and.1pack/day [20%of smokers])was associatedwith
clinically and statistically significantly reduced DFS
and OS compared to NS. The absolute magnitude of
the reduction in survival of 18% is important, and
both transplanters and high-dose smoking patients
should be aware of these data. This effect is mediated
by a higher TRM (50% versus 28%), and although
the RR of relapse was higher in smokers overall, it
was not increased in the high-dose group. Analysis of
univariate outcomes (Table 3) suggested an effect on
IP (P5 .018), but no effect on bronchopneumonia or
bronchiolitis obliterans. The effects of smoking on
TRM may not be just pulmonary, as smoking has the
potential to affect the function of other vital organs.
Despite these findings we are not advocating that trans-
planters should withhold this therapy from this patient
subset nor should it affect a patient’s health insurance
status. Future research should focus on reducing
the higher TRM in the high-dose smoking group.
Reduced-intensity conditioning (RIC) is one possible
way of achieving this.We did not see significant effects
onTRMand survival in the lower dose smoking group;
this is biologically plausible, but a prospective study
would be of value in clarifying this finding. It is worth
noting that there were nomajor differences in outcomein the recipients of unrelated donor transplants; it is
possible that the higherTRMassociatedwith unrelated
transplantation masked a separate effect of smoking.
Small numbers in the high-dose group reduced the
chance of demonstrating significant differences.
Table 5. Reported Causes of Death of Patients $18 Years
Receiving HLA-Identical Sibling Donor Transplants for CML in
First Chronic Phase, Reported to the CIBMTR, 1990-2004
Smokers
Nonsmokers Low Dose High Dose
Causes N (%) N (%) N (%)
GVHD 132 (24) 32 (23) 9 (18)
IPN 95 (18) 24 (17) 9 (18)
Infection 103 (19) 31 (22) 13 (25)
New malignancy 5 (1) 5 (4) 1 (2)
Organ failure 53 (10) 14 (10) 9 (18)
Other cause 80 (15) 20 (14) 8 (16)
Primary disease 73 (13) 15 (11) 2 (4)
GVHD indicates graft-versus-host disease; IPN, interstitial pneumonitis;
CIBMTR, Center for International Blood and Marrow Transplant
Research; CML, chronic myelogenous leukemia.
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however, this was only seen in low-dose smokers
(RR5 1.75) on multivariate analysis. The lack of an
effect in high-dose smokers may result from the higher
TRM in this group. The apparent effect in low-dose
smokers was not because of RIC or via an effect on
GVHD. Smoking may be immunomodulatory (in-
flammatory bowel disease is more common in
smokers) [13]; donor T cells may be rendered less
able to mediate a graft-versus-leukemia (GVL) effect.
However, we do not have data about smoking post-
transplant. Amouse model showed effects on dendritic
cells and on T cell proliferation [14]. The smoking sta-
tus of the donor might be of greater importance in this
effect, and there is a high incidence of smoking in the
siblings of smokers [15]. This could explain the fact
that there was no increase in relapse in unrelated donor
recipients who tend to be healthy and smoke less.
However, the minority of smokers who continue to
smoke posttransplant may affect the donor T cells on
a continuing basis. In a study from Boston [16] the
risk of relapse appeared to be higher in smokers and in-Table 6. Reported Causes of Death of Patients$ 18 Years
Receiving Unrelated Donor Transplants for CML in First
Chronic Phase, Reported to the CIBMTR, 1990-2004
Smokers
Nonsmokers Low Dose High Dose
Causes N (%) N (%) N (%)
GVHD 60 (21) 18 (24) 7 (33)
IPN 59 (20) 9 (12) 5 (24)
Infection 79 (27) 17 (23) 2 (10)
New malignancy 3 (1) 1 (1) 1 (5)
Organ failure 27 (9) 14 (19) 2 (10)
Other cause 43 (15) 8 (11) 3 (14)
Primary disease 20 (7) 8 (11) 1 (5)
GVHD indicates graft-versus-host disease; IPN, interstitial pneumonitis;
CIBMTR, Center for International Blood and Marrow Transplant
Research; CML, chronic myelogenous leukemia.creased with each pack year of exposure. In that study,
14 of 17 patients who had relapse smoked (P5 .01).
The same group, however, found no effect of smoking
on 1-year survival [17].
Additionally, there may be effects on pulmonary
function, although reports vary. Twenty years ago
the Seattle group [18] found that smoking was associ-
ated with a lower FEV1/FVC at 1 year posttransplant
(P5 .01); the effect on pulmonary function tests
(particularly gas transfer) at 1 year was confirmed by
a French group [19]. Gas transfer was impaired at base-
line and during the first year posttransplant in
smokers, including in transplants with non-TBI condi-
tioning [20]. Savani and colleagues [3] found that
smoking increased TBI-related pulmonary mortality
5-fold, but that this effect could be reduced by giving
a high CD34 dose. However, effects on pulmonary
outcomes were not seen after all studies. Ho and col-
leagues [4] from Boston found no increase in severe
pulmonary complications posttransplant.
This study has limitations that should influence
data interpretation. First, the registry forms did not
capture whether the smoking was current or past or
if smoking was resumed after transplant. Second, we
had limited ‘‘dose’’ data and could not calculate pack
years accurately in many cases, which may explain
the inconsistent dose-related findings. Third, the
self-reported smoking history may be inaccurate and
there may be some underreporting. Fourth, knowl-
edge of the demographic factors that are associated
with smoking [21] would have improved our ability
to make conclusions. Finally, in retrospect, it might
have been informative to examine outcomes in other
transplant eligible diseases, as smoking may have
more effect in patients who had substantial pretrans-
plant chemotherapy. In many countries fewer patients
with early phase CML proceed to transplant now;
however, the EBMT risk score for CML has been val-
idated for other diseases, and it seems likely that the
effect seen in CML patients would also be seen in
patients with other hematologicmalignancies. Patients
with diseases such as acute leukemia are exposed to
recurrent episodes of neutropenia, which has the
potential to augment some of the organ-related effects
of smoking including pulmonary infection.
Further examination of this issue would require a
prospective study; this would have several advantages.
There would be more accurate correlation of past and
current exposure of patients and their donors with
outcome, and this could be associated with regular
pulmonary function tests. There would also be the
opportunity to collect patient-reported outcomes and
determine if there are effects on rehospitalization, chest
infections, and reemployment. Furthermore, prospec-
tive demographic data could be collected, allowing
the study to separate the effects of smoking from
effects that the different demographic characteristics
Biol Blood Marrow Transplant 15:1277-1287, 2009 1287Effect of Smoking on Transplant Outcomesthat smokers may have. Nonetheless, this study pres-
ents clinically important findings. It is the largest
study ever that examines the impact of smoking on
transplant outcome, and contains data that patients
and transplanters will be able to use in making clinical
decisions.ACKNOWLEDGMENTS
Financial disclosure: The CIBMTR is supported by
Public Health Service Grant U24-CA76518 from the
National Cancer Institute, the National Institute of
Allergy and Infectious Diseases, and the National
Heart, Lung and Blood Institute; Office of Naval Re-
search; Health Resources and Services Administration
(DHHS); and grants from AABB; Aetna; American So-
ciety for Blood and Marrow Transplantation; Amgen,
Inc.; anonymous donation to the Medical College of
Wisconsin; Association of Medical Microbiology and
Infectious Disease Canada; Astellas Pharma US, Inc.;
Baxter International, Inc.; Bayer HealthCare Pharma-
ceuticals; Blood Center of Wisconsin; Blue Cross and
Blue Shield Association; Bone Marrow Foundation;
Canadian Blood and Marrow Transplant Group; Cel-
gene Corporation; CellGenix, GmbH; Centers for
Disease Control and Prevention; ClinImmune Labs;
CTI Clinical Trial and Consulting Services; Cubist
Pharmaceuticals; Cylex Inc.; CytoTherm; DOR Bio-
Pharma, Inc.; Dynal Biotech, an Invitrogen Company;
Enzon Pharmaceuticals, Inc.; European Group for
Blood and Marrow Transplantation; Gambro BCT,
Inc.; Gamida Cell, Ltd.; Genzyme Corporation; His-
togenetics, Inc.; HKS Medical Information Systems;
Hospira, Inc.; Infectious Diseases Society of America;
Kiadis Pharma; Kirin Brewery Co., Ltd.; Merck &
Company; The Medical College of Wisconsin; MGI
Pharma, Inc.; Michigan Community Blood Centers;
Millennium Pharmaceuticals, Inc.; Miller Pharmacal
Group; Milliman USA, Inc.; Miltenyi Biotec, Inc.;
National Marrow Donor Program; Nature Publishing
Group; New York Blood Center; Novartis Oncology;
Oncology Nursing Society; Osiris Therapeutics, Inc.;
Otsuka Pharmaceutical Development & Commercial-
ization, Inc.; Pall Life Sciences; PDL BioPharma,
Inc; Pfizer Inc.; Pharmion Corporation; Saladax
Biomedical, Inc.; Schering Plough Corporation; Soci-
ety for Healthcare Epidemiology of America; Stem-
Cyte, Inc.; StemSoft Software, Inc.; Sysmex; Teva
Pharmaceutical Industries; The Marrow Foundation;
THERAKOS, Inc.; Vidacare Corporation; Vion Phar-
maceuticals, Inc.; ViraCor Laboratories; ViroPharma,
Inc.; and Wellpoint, Inc. The views expressed in this
article do not reflect the official policy or position of
the National Institutes of Health, the Department of
the Navy, the Department of Defense, or any other
agency of the U.S. Government.REFERENCES
1. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow trans-
plants from unrelated donors for patients with chronic myeloid
leukemia. N Engl J Med. 1998;338:962-968.
2. Marks DI, Cullis JO, Ward KN, et al. Allogeneic bone marrow
transplantation for chronic myeloid leukemia using sibling and
volunteer unrelated donors. A comparison of complications in
the first 2 years. Ann Intern Med. 1993;119:207-214.
3. Savani BN, Montero A, Wu C, et al. Prediction and prevention
of transplant-relatedmortality from pulmonary causes after total
body irradiation and allogeneic stem cell transplantation. Biol
Blood Marrow Transplant. 2005;11:223-230.
4. Ho VT,Weller E, Lee SJ, Alyea EP, Antin JH, Soiffer RJ. Prog-
nostic factors for early severe pulmonary complications after
hematopoietic stem cell transplantation. Biol Blood Marrow
Transplant. 2001;7:223-229.
5. Tichelli A, Bhatia S, Socie G. Cardiac and cardiovascular conse-
quences after haematopoietic stem cell transplantation. Br
J Haematol. 2008;142:11-26.
6. Lowe T, Bhatia S, Somlo G. Second malignancies after alloge-
neic hematopoietic cell transplantation. Biol Blood Marrow
Transplant. 2007;13:1121-1134.
7. Office of Population Censuses and Surveys. General Household
Survey 1978: Cigarette Smoking.OPCSmonitor.Reference GHS
79/2. 1978.
8. JhaP,PetoR,ZatonskiW,BorehamJ, JarvisMJ,LopezAD.Social
inequalities inmalemortality, and inmalemortality fromsmoking:
indirect estimation from national death rates in England and
Wales, Poland, and North America. Lancet. 2006;368:367-370.
9. McKee SA, Harrison EL, O’Malley SS, et al. Varenicline re-
duces alcohol self-administration in heavy-drinking smokers.
Biol Psychiatry. 2009;66:185-190.
10. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for
patients with chronicmyeloid leukaemia before allogeneic blood
or marrow transplantation. Chronic Leukemia Working Party
of the European Group for Blood andMarrow Transplantation.
Lancet. 1998;352:1087-1092.
11. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods
for the analysis and presentation of the results of bone marrow
transplants. Part I: unadjusted analysis. Bone Marrow Transplant.
2001;28:909-915.
12. Rigotti NA. Clinical practice. Treatment of tobacco use and
dependence. N Engl J Med. 2002;346:506-512.
13. Ekbom A, Brandt L, Granath F, Lofdahl CG, Egesten A.
Increased risk of both ulcerative colitis and Crohn’s disease in
a population suffering from COPD. Lung. 2008;186:167-172.
14. Robbins CS, Franco F, Mouded M, Cernadas M, Shapiro SD.
Cigarette smoke exposure impairs dendritic cell maturation
and T cell proliferation in thoracic lymph nodes of mice.
J Immunol. 2008;180:6623-6628.
15. Becklake MR, Ghezzo H, Ernst P. Childhood predictors of
smoking in adolescence: a follow-up study of Montreal school-
children. CMAJ. 2005;173:377-379.
16. ChangG,Orav EJ,McNamaraT, TongMY, Antin JH.Depres-
sion, cigarette smoking, and hematopoietic stem cell transplan-
tation outcome. Cancer. 2004;101:782-789.
17. Chang G, Orav EJ, Tong MY, Antin JH. Predictors of 1-year
survival assessed at the time of bone marrow transplantation.
Psychosomatics. 2004;45:378-385.
18. Clark JG, Schwartz DA, Flournoy N, Sullivan KM,
Crawford SW, Thomas ED. Risk factors for airflow obstruction
in recipients of bone marrow transplants. Ann Intern Med. 1987;
107:648-656.
19. Socie G,Mary JY, EsperouH, et al. Health and functional status
of adult recipients 1 year after allogeneic haematopoietic stem
cell transplantation. Br J Haematol. 2001;113:194-201.
20. LundMB,BrinchL,Kongerud J, Boe J. Lung function 5 yrs after
allogeneic bonemarrow transplantation conditionedwith busul-
phan and cyclophosphamide. Eur Respir J. 2004;23:901-905.
21. Marmot M. Smoking and inequalities. Lancet. 2006;368:
341-342.
